Article info

Download PDFPDF

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Authors

  1. p Wilkinsonr{at}MedImmune.com
View Full Text

Citation

Poon E, Mullins S, Watkins A, et al
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Publication history

  • Received April 12, 2017
  • Accepted July 13, 2017
  • First published August 15, 2017.
Online issue publication 
August 15, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.